Would You Trust a Treatment Testimonial from Someone Who Doesn’t Exist?

Meet Mia Zelu. She has luminous skin, flawless symmetry, and millions of followers across Instagram and TikTok. She’s been seen “trying” injectables, endorsing prescription topicals, and modeling laser results for skincare brands. She’s also never been to a physician’s office and doesn’t have pores—or even skin.

Mia is not human, she’s an AI-generated influencer: a product of generative artificial intelligence trained to look like the perfect patient and speak like the ideal brand ambassador. She’s photogenic, always available, and immune to controversy.

She is also at the center of a growing ethical debate:

Should pharmaceutical and medical aesthetics companies use AI influencers to market healthcare products and services?

As synthetic personalities gain ground in digital campaigns—especially in dermatology, aesthetics, mental health, and wellness—executives must navigate a minefield of regulatory, ethical, and reputational risks. The question is no longer can we use AI avatars to promote pharmaceuticals. The question is should we?

The Allure of Artificial Ambassadors

The appeal of AI-generated influencers is easy to understand. They don’t require contracts or photo shoots. They don’t age, miss deadlines, or generate PR crises. And they’re engineered to drive engagement—often outperforming their human counterparts in reach and aesthetic appeal.

For brand teams under pressure to cut costs and boost efficiency, synthetic influencers like Mia are a dream. They offer: Infinite content on demand, total message control, visual perfection tuned to target demographics and no union, agency, or compliance headaches.

In a competitive market where social media is a primary battleground for attention, AI-generated personas feel like a future-proof solution.

But in pharmaceuticals and healthcare-adjacent industries, perception is not enough. These are industries grounded in science, patient outcomes, and public trust. And that’s where the ethical calculus changes.

Where Ethics in AI Use Get Complicated

A. Are We Misleading Consumers?

An AI-generated avatar like Mia may “demonstrate” the benefits of a laser treatment or injectable biologic. But her results aren’t real. They’re rendered. She doesn’t have skin that heals or scars. She never metabolized a drug or experienced adverse effects.

When synthetic influencers are used without clear disclosure, it risks misleading consumers. Even when AI personas aren’t making explicit claims, the visual suggestion of efficacy—a smoother forehead, clearer skin, or brighter eyes—can create deceptive impressions.

In pharmaceutical advertising, this is particularly fraught. The FDA mandates truthful, not misleading presentation of risks and benefits. If an AI-generated image implies a result that hasn’t been clinically proven or simply isn’t possible in real life, that may constitute a regulatory violation.

B. What About Informed Consent and Patient Expectations?

Pharmaceutical products—particularly in dermatology, aesthetics, psychiatry, and endocrinology—are often linked to sensitive issues: body image, identity, and self-esteem.

When an AI influencer with unattainable, algorithmic perfection becomes the face of a treatment campaign, it can warp patient expectations. Consumers may walk into clinics expecting to look like Mia post-procedure, only to find out that real results don’t come with digital airbrushing.

This disconnect can erode trust not only in the brand, but in the clinician-patient relationship.

C. Who Is Accountable for AI-Driven Claims?

If a synthetic avatar misleads consumers—even unintentionally—who bears responsibility?

• The marketing agency that created the campaign?
• The AI vendor who built the persona?
• The pharmaceutical company funding the ad?
• The platform that distributed it?

With human influencers, there’s a traceable source. With AI avatars, accountability becomes diffuse. This opens the door to legal uncertainty, reputational risk, and regulatory scrutiny.

Executives must be proactive in defining ownership and liability around AI-generated promotional content before it’s tested in court or investigated by regulators.

D. Is Trust in Pharma Being Eroded in the Process?

Pharmaceutical brands operate in a high-trust environment. They ask patients to put their health—and sometimes their lives—in their hands. That trust is hard-won and easily lost.

Using AI avatars to promote prescription treatments, even if legally permissible, may undermine the credibility of the brand or therapeutic area. If patients realize they were influenced by a bot and not a real person, it can create cynicism and backlash.

In an era where medical misinformation and health skepticism are rampant, transparency is not optional. It’s essential for maintaining long-term trust.

E. Are We Displacing Human Expertise and Experience?

AI-generated influencers aren’t just replacing models, they’re replacing dermatologists, nurses, pharmacists, and patient advocates in some campaigns. Instead of a real patient telling their treatment story, we now see perfectly scripted, digitally rendered avatars delivering testimonials.

This raises not just ethical questions but strategic ones: Are we devaluing human insight and lived experience? Are we silencing the voices of those who have actually used the product or cared for patients?

Real patient stories and clinician perspectives are irreplaceable. Brands that neglect them in favor of digital perfection risk losing the authenticity that drives trust and connection.

Recommendations for Pharmaceutical Executives

The rise of AI influencers is not a passing trend, it’s a permanent shift in the digital marketing landscape. Pharmaceutical leaders must respond with thoughtful governance and forward-looking strategies.

1. Establish Clear Disclosure Guidelines. AI-generated content must be clearly labeled as synthetic. Visual watermarks, voiceover disclosures, and content tags can help ensure audiences know what they’re seeing is simulated and not real.
2. Integrate AI into Medical, Legal, and Regulatory (MLR) Review Workflows. AI personas used in branded campaigns should go through MLR review just like any other creative asset. Consider risk thresholds: Are you using AI to illustrate a mechanism of action or to simulate patient outcomes?
3. Prioritize Ethical Oversight. Develop an internal AI Marketing Ethics Council composed of legal, medical, compliance, and digital strategy experts. This group can vet use cases, evaluate audience risk, and ensure campaigns align with company values and regulatory expectations.
4. Co-Create with Real Patients and Providers. Use AI to support human storytelling, not replace it. Consider hybrid approaches in which real clinicians narrate alongside animated visualizations, or where AI avatars model outcomes based on anonymized, aggregate clinical data and not fictional perfection.
5. Advocate for Industry Standards. Work with industry associations, the FDA, and the FTC to help shape the evolving regulatory framework around AI-generated advertising in healthcare. By taking the lead, your company demonstrates credibility and foresight.

Final Thought: In Healthcare, Real Still Matters

AI influencers like Mia Zelu represent the cutting edge of digital storytelling. But when applied to pharmaceutical marketing, innovation must be balanced with integrity.

The goal of healthcare communication is not just to dazzle, it’s to inform, educate, and empower patients to make safe, evidence-based decisions. That mission is too important to hand over entirely to synthetic faces and algorithmic charm.

So yes, AI will have a place in the future of pharma marketing, but only if ethics, transparency, and patient trust lead the way.

Disclaimer: Mia Zelu is a fictional AI influencer used in this article to illustrate ethical considerations in pharmaceutical advertising. No reference to actual companies, campaigns, or products is intended.

About the Author

Dr. Thani Jambulingam is a professor in food, pharma and healthcare at Erivan K. Haub School of Business, Saint Joseph’s University, Philadelphia. He is a healthcare innovation strategist and contributing writer to Pharmaceutical Executive. Their work focuses on the intersection of emerging technologies, medical ethics, and commercial strategy.